Boisjoly H M, Park N H, Pavan-Langston D, De Clercq E
Arch Ophthalmol. 1983 Nov;101(11):1782-6. doi: 10.1001/archopht.1983.01040020784025.
Acyclovir is a potent and selective antiviral agent. Unfortunately, drug-resistant (acyclovir-resistant) mutants have already been reported in herpes simplex virus type 1 (HSV-1) orofacial infections. We have developed a laboratory acyclovir-resistant HSV-1 mutant. The natural course of acyclovir-resistant HSV-1 keratitis was found to be less virulent than that observed in wild type HSV-1 keratitis, but the rate of ganglionic latency was as high as that induced by the parental strain. In vitro studies and in vivo observation of rabbit corneas infected with acyclovir-resistant HSV-1 both demonstrated a significant sensitivity to vidarabine and bromovinyldeoxyuridine ([E]-5-[2-bromovinyl]-2'-deoxyuridine). The thymidine kinase activity of the acyclovir-resistant mutant was 69% of that of the wild type HSV-1.
阿昔洛韦是一种强效且具有选择性的抗病毒药物。不幸的是，在单纯疱疹病毒1型（HSV-1）口腔面部感染中已报道了耐药（阿昔洛韦耐药）突变体。我们已研发出一种实验室阿昔洛韦耐药HSV-1突变体。发现阿昔洛韦耐药HSV-1角膜炎的自然病程比野生型HSV-1角膜炎的毒性小，但神经节潜伏率与亲本菌株诱导的一样高。对感染阿昔洛韦耐药HSV-1的兔角膜进行的体外研究和体内观察均表明对阿糖腺苷和溴乙烯脱氧尿苷（[E]-5-[2-溴乙烯基]-2'-脱氧尿苷）有显著敏感性。阿昔洛韦耐药突变体的胸苷激酶活性为野生型HSV-1的69%。
